Following an application from the Institute of Biotechnology, Sera and Vaccines Biomed SA, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactoral on the living probiotic bacteria (Question No EFSA-Q-2008-480) [The EFSA Journal (2008) 862, pp. 1-2.]. The claim proposed by the applicant was worded as follows: ‘Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infants’.
Recital 21, Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refu…
In forcesince 29 Oct 2009